{"name":"Luis Fernando Simoneti","slug":"luis-fernando-simoneti","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ketoprofen and Omeprazole","genericName":"Ketoprofen and Omeprazole","slug":"ketoprofen-and-omeprazole","indication":"Rheumatoid arthritis with gastric protection","status":"marketed"}]}],"pipeline":[{"name":"Ketoprofen and Omeprazole","genericName":"Ketoprofen and Omeprazole","slug":"ketoprofen-and-omeprazole","phase":"marketed","mechanism":"Ketoprofen inhibits prostaglandin synthesis via COX inhibition to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers.","indications":["Rheumatoid arthritis with gastric protection","Osteoarthritis with gastric protection","Chronic pain conditions requiring NSAID therapy with reduced GI risk"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}